SCHEMBL1836679

SCHEMBL1836679

Nc1cc(-c2cc3c(-c4cccc5[nH]ccc45)ccnc3[nH]2)ccn1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 2/20 0.46
DYRK1A Q13627 5/20 0.43
EGFR P00533 3/20 0.42
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
CDC7 O00311 2/20 0.40
MAPT P10636 1/20 0.39
BTK Q06187 1/20 0.39
CHUK O15111 2/20 0.39
INSR P06213 2/20 0.39
MAPK8 P45983 2/20 0.39
CAMKK2 Q96RR4 2/20 0.39
DHFR P00374 1/20 0.38
NUDT1 P36639 1/20 0.38
ASH1L Q9NR48 1/20 0.38
CLK2 P49760 2/20 0.38
CLK3 P49761 1/20 0.38
PRKCI P41743 1/20 0.38
MAPK14 Q16539 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12354047 0.84 PIK3CD (0.43) PIK3CDDYRK1AEGFRPIK3CBPIK3CG
SCHEMBL1837314 0.81 CHUK (0.62) PIK3CDEGFRCHUKINSRMAPK8
SCHEMBL1838419 0.81 CDC7 (0.47) DYRK1AEGFRCDC7MAPTBTK
SCHEMBL1838178 0.79 CDC7 (0.51) DYRK1AEGFRCDC7CHUKINSR
SCHEMBL1841792 0.74 EGFR (0.53) EGFRCHUKINSRMAPK8CAMKK2
SCHEMBL1840342 0.74 IGF1R (0.60) PIK3CDDYRK1APIK3CBPIK3CGCHUK
SCHEMBL1840172 0.74 CHUK (0.56) EGFRCDC7CHUKINSRMAPK8
SCHEMBL1838420 0.73 BRD4 (0.43) EGFRCHUKINSRMAPK8CAMKK2
SCHEMBL1840648 0.73 CHUK (0.60) EGFRCDC7CHUKINSRMAPK8
SCHEMBL1839697 0.73 NEK1 (0.48) CHUKINSRMAPK8CAMKK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2011526931-A 2011-10-20 JP claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US claimed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 CN claimed
EP-2320895-A2 CDK MODULATORS Exelixis, Inc. (US) 2011-05-18 EP claimed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO claimed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
US-20110201599-A1 CDK Modulators EXELIXIS, INC. (US) 2011-08-18 US disclosed
CN-102143746-A CDK modulators EXELIXIS INC 2011-08-03 CN disclosed
WO-2010003133-A2 CDK MODULATORS EXELIXIS INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201599-A1 CDK Modulators CDK3, CDK1, CDKL1 PIK3CD 297/4885DYRK1A 546/4885EGFR 1213/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.